Grant: $246,930 - National Institutes of Health - Aug. 1, 2009
No votes have been cast for this award yet
Award Description: These studies will lead to a more comprehensive understanding of how EpoR signals through JAK2 to regulate erythropoiesis, and how JAK2 mutations contribute to myeloproliferative disorders and lukemia.
Project Description: Our research focuses on Janus tyrosine kinase 2 (JAK2), which is a key regulator for hematopoiesis. Gain-of-function JAK2 mutations has now superseded Bcr-Abl as the most frequent abnormality in myeloproliferative neoplasms (MPNs). However, it is not clear how one of the mutations is associated with three distinct MPNs. We show that four different activating JAK2 mutants elicited distinct hematopoietic phenotypes in a murine bone marrow transplant model, providing direct evidence that mutations in JAK2 are sufficient to generate complex phenotypes. Research funded by ARRA will utilize these mutants as tools to dissect how aberrant JAK2 signaling contribute to MPN. Huiyu Yao, a postdoctoral fellow was hired for this work. Due to the visa application process, he is expected to start November 1, 2009. In the meantime, essential reagents for this project have been generated or purchased.
Jobs Summary: N/A (Total jobs reported: 0)
Project Status: Less Than 50% Completed
This award's data was last updated on Aug. 1, 2009. Help expand these official descriptions using the wiki below.